Q-omics provides the consensus-scored OR10V1 profile across patient tissues and cancer cell-line models. OR10V1 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, OR10V1 is differentially expressed in 5, with the highest sampling consensus in BRCA. Additionally, OR10V1 RNA expression shows 6,452 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight SKCM, BRCA, and STAD as cancer lineages where OR10V1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for OR10V1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes OR10V1 survival associations across molecular data types. OR10V1 RNA expression shows survival associations in the most cancer types (15), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible OR10V1 RNA expression–survival associations across cancer types. High OR10V1 expression shows unfavorable associations in SKCM, MESO, CESC, COAD and KICH, but favorable associations in ESCA. The SKCM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for OR10V1 RNA expression.
This table summarizes OR10V1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for OR10V1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. OR10V1 shows lower tumor expression in BRCA, LUSC, STAD and PRAD and higher tumor expression in HNSC. The BRCA box plot shows higher OR10V1 RNA expression in normal versus tumor tissue (log2 FC = −0.025, t-test p < 0.001).
This table shows molecular features associated with OR10V1 in patient tissues and cancer cell lines. In patient samples, OR10V1 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, OR10V1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in BONE and BLOOD_Leukemia.
